This company develops next-generation gene-editing technology, XenoArray™, capable of performing parallel edits across thousands of base pairs in a single experiment. Their platform accelerates the design-build-test-learn cycle for strain engineering by integrating custom microfluidic hardware and AI-driven biological databases. This approach significantly expands the accessible genetic search space for developing enhanced proteins and engineered organisms.
Funding
$600K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional gene editing techniques using CRISPR are limited by single edits, small gene inserts, low throughput, long experiment times, and high error rates, hindering rapid advancement in biotechnology. The iterative nature of these methods restricts the ability to explore a large genetic search space efficiently.
Solution
Xenomics offers XenoArray™, a scaled genome editing platform that enables parallel edits and large gene inserts, significantly accelerating the design-build-test-learn cycle. This technology allows for the creation of thousands of unique cell lines in a single experiment, vastly expanding the genetic search space compared to traditional CRISPR methods. By integrating wetware, hardware, and software components, XenoArray™ streamlines strain engineering and analysis. The platform combines microfluidic cell handling, biological databases, and AI to enhance the efficiency of gene knock-ins and the discovery of proteins with enhanced properties.
Target Audience
Xenomics targets biotechnology companies and research institutions seeking to accelerate gene editing processes for applications in biopharmaceuticals, vaccines, cell therapies, cultured meats, and other bioengineered products.
Features
- Parallel editing of up to 3,000 unique cell strains simultaneously
- Capability for 8,000 base pair gene inserts
- Scaled genome editing generating a search space of over 160 quadrillion combinations
- Microfluidic cell handling and analysis for parallel fermentation of 10-15k strains and assaying 9k strains per day
- Integration of biological databases and AI to streamline strain engineering and improve the design-build-test-learn model